CLDI

Calidi Biotherapeutics, Inc. (CLDI) | Rumor.io

Calidi Biotherapeutics

CLDI

Attention (50-day avg)0%

Attention rank (50-day avg)#3,137

Bullish sentiment (50-day avg)57%

Price to earnings ratio0.75

Market capitalization2.8M

Earnings per share-37

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-20.1M

Social

What share of all stock conversation is about CLDI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% -0.01

Sep 23

Calidi Biotherapeutics, Inc. (CLDI) has received FDA news that could lead to a significant price increase tomorrow.
CLDI has raised $1.2 million in a registered direct offering at $1.17 per share.
The stock is showing a significant increase in volume, indicating a potential "pop" in its price.

Generated by AI

Sentiment

Of the messages about CLDI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	61.54%	61.54% -18.46	80.27% -12.82
Bearish	—	38.46%	38.46% +18.46	19.73% +12.82

Bullish· May 27

Calidi Biotherapeutics' ($CLDI) lead RedTail platform candidate, CLD-401, is nearing IND filing, a key catalyst for the company.
The company's RedTail platform has shown promising preclinical data, including immune activation and tumor-targeting capability, with multiple payload programs in development.
A recent cash raise of $6M-$6.5M will help extend CLDI's runway towards upcoming milestones, including new AACR and ASCO cancer data presentations and strategic partnerships.

Bearish· May 27

$CLDI's recent conference presentation was seen as a negative, implying the company isn't legitimate enough to speak at industry events.
The lack of significant news and catalysts for $CLDI was highlighted, suggesting a lack of momentum for the stock.
$CLDI's price has been volatile, with some users expecting a sharp decline, similar to a "hot air balloon" that rises quickly but then crashes.

Generated by AI

Topics

Of the messages about CLDI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	33.33%	86.39%
Technical Analysis	—	100%	66.67%	13.42%
Analysts	—	0%	0%	0%
Controversies	—	0%	0%	0.1%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0.1%

Announcements· Jul 29

Calidi Biotherapeutics received FDA Fast Track designation for CLD-201 (SuperNova), a first-in-class stem-cell loaded viral therapy for the treatment of patients with soft tissue sarcoma.
The company previously obtained FDA IND clearance for CLD-201 in April 2025 and will no longer proceed with a previously approved reverse stock split.
Calidi Biotherapeutics raised $4.6M via warrant exercise, providing cash for its runway, and is developing its RedTail virotherapy platform targeting metastatic cancers.

Technical Analysis· Jul 29

$CLDI broke out with soaring volume and an RSI that tapped into overbought territory, indicating bullish momentum.
A falling wedge pattern is forming on $CLDI, suggesting a potential trend reversal.
$CLDI's MACD is showing a potential reversal on the 1-minute chart, with the 5-minute chart still looking questionable.

Generated by AI

Community

Of the messages about CLDI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	85.71%	86.11%	42.99%
Newcomers	—	14.29%	13.89%	57.01%

Regulars· Sep 23

* The FDA news about CLDI could be a significant catalyst for the stock, potentially leading to a huge increase tomorrow.
* CLDI's nano float of 600k is currently at $1.52, which is a relatively small number compared to other stocks like MSS, but could still have a significant impact on the stock's price.
* CLDI's recent registered direct offering has raised $1.2 million, with shares being sold at $1.17 per share, which could have implications for the stock's price and the company's financial situation.

Newcomers· Jul 24

Newcomers to CLDI are excited about its potential for a large price increase, with some predicting a spike to $0.17 or higher.
The company has announced a reverse stock split to boost investor appeal, and some users are optimistic about its prospects for a cancer cure.
Users are discussing the company's strong base formation and creeping up in price, with some predicting a "run" or accumulation opportunity.

Generated by AI

SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced that it has entered into a definitive stock purchase agreement with certain accredited investors and/or qualified institutional buyers for the purchase and sale of 1,025,640 shares of the Company’s common stock, in a registered direct offering, at a per share purchase price o

12d agoYahoo Finance

Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announces that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel. Eric Poma, Ph.D., Chief Executive Officer of Calidi Biotherapeutics will hold one-on-one meetin

21d agoYahoo Finance

Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Received positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a first-in-human study targeting first patient dosing in Q1 2027 Showcased the versatility of its RedTail platform at the 2026 ASCO Annual Meeting with new CLD-501 data demonstrating the simultaneous in situ delivery of a TROP-2-targeted tumor-localized T-cell engager (TCE) alongside a T-cell amplifier; the Company is also advancing its EpCam-targeted in situ TCE prog

1mo agoYahoo! Finance Canada

Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference

SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, presented on July 23, 2026, at the American Association for Cancer Research Drug Discovery and Development (AACR D3) Conference in Boston, MA. The Company presented new data on its CLD-401 program that it expects to enter the clinic in the first quarter

2mo agoYahoo Finance

Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers

Company receives positive pre-IND feedback from US FDA for CLD-401, indicating agreement on its current development strategy as it advances towards a first-in-human study; targeting dosing first patient in Q1 2027 Company demonstrated the versatility of the RedTail platform with new CLD-501 data demonstrating the simultaneous in situ delivery of a TROP-2-targeted tumor-localized T-cell engager (TCE) alongside a T-cell amplifiers. The Company is also advancing its EpCam-targeted In Situ TCE progr

2mo agoYahoo Finance

Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026

SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a biotechnology company pioneering the development of targeted genetic medicine, announced today that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-16 (the “Reverse Stock Split”). The Company’s common stock is expected to commence trading on a split-adjusted basis when the NYSE American market opens on July 31, 2026 unde

2mo agoYahoo Finance

Also Discussed

Investors talking about CLDI also mention

#	Name	Attention
1	ProKidney Corp. Class A Ordinary SharesPROK	0%0
2	RVPH - Reviva Pharmaceuticals Holdings, Inc.	——
3	Globavend Holdings LimitedGVH	0%0
4	Erayak Power Solution Group Inc. Class A Ordinary SharesRAYA	0%0
5	Telomir Pharmaceuticals, Inc.TELO	0%0
6	Nocera, Inc.NCRA	0%new
7	Aligos Therapeutics, Inc.ALGS	0%new
8	Aspire Biopharma Holdings, Inc.ASBP	0%new
9	Azitra Inc.AZTR	0%0
10	Splash Beverage Group Inc.SBEV	0%new

Calidi Biotherapeutics, Inc.

Healthcare
Biotechnology

Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies that deliver genetic medicines to sites of disease. The company’s current programs center on stem cell-based and oncolytic virus platforms designed to transport therapeutic payloads directly into tumors while helping protect them from premature immune clearance. Its portfolio includes product candidates for cancers such as high-grade glioma and solid tumors, reflecting a focus on oncology and precision delivery methods. Calidi Biotherapeutics also works across systemic and localized treatment approaches, using proprietary cell-based technologies to support tumor targeting, immune activation, and controlled payload delivery. Headquartered in San Diego, California, Calidi Biotherapeutics plays a role in the broader biopharmaceutical market as a developer of advanced immuno-oncology and gene therapy solutions.

Website

Location

4475 Executive Drive

San Diego, CA, 92121

United States

Social

What share of all stock conversation is about CLDI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% -0.01

Sep 23

Calidi Biotherapeutics, Inc. (CLDI) has received FDA news that could lead to a significant price increase tomorrow.
CLDI has raised $1.2 million in a registered direct offering at $1.17 per share.
The stock is showing a significant increase in volume, indicating a potential "pop" in its price.

Generated by AI

Sentiment

Of the messages about CLDI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	61.54%	61.54% -18.46	80.27% -12.82
Bearish	—	38.46%	38.46% +18.46	19.73% +12.82

Bullish· May 27

Calidi Biotherapeutics' ($CLDI) lead RedTail platform candidate, CLD-401, is nearing IND filing, a key catalyst for the company.
The company's RedTail platform has shown promising preclinical data, including immune activation and tumor-targeting capability, with multiple payload programs in development.
A recent cash raise of $6M-$6.5M will help extend CLDI's runway towards upcoming milestones, including new AACR and ASCO cancer data presentations and strategic partnerships.

Bearish· May 27

$CLDI's recent conference presentation was seen as a negative, implying the company isn't legitimate enough to speak at industry events.
The lack of significant news and catalysts for $CLDI was highlighted, suggesting a lack of momentum for the stock.
$CLDI's price has been volatile, with some users expecting a sharp decline, similar to a "hot air balloon" that rises quickly but then crashes.

Generated by AI

Topics

Of the messages about CLDI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	33.33%	86.39%
Technical Analysis	—	100%	66.67%	13.42%
Analysts	—	0%	0%	0%
Controversies	—	0%	0%	0.1%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0.1%

Announcements· Jul 29

Calidi Biotherapeutics received FDA Fast Track designation for CLD-201 (SuperNova), a first-in-class stem-cell loaded viral therapy for the treatment of patients with soft tissue sarcoma.
The company previously obtained FDA IND clearance for CLD-201 in April 2025 and will no longer proceed with a previously approved reverse stock split.
Calidi Biotherapeutics raised $4.6M via warrant exercise, providing cash for its runway, and is developing its RedTail virotherapy platform targeting metastatic cancers.

Technical Analysis· Jul 29

$CLDI broke out with soaring volume and an RSI that tapped into overbought territory, indicating bullish momentum.
A falling wedge pattern is forming on $CLDI, suggesting a potential trend reversal.
$CLDI's MACD is showing a potential reversal on the 1-minute chart, with the 5-minute chart still looking questionable.

Generated by AI

Community

Of the messages about CLDI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	85.71%	86.11%	42.99%
Newcomers	—	14.29%	13.89%	57.01%

Regulars· Sep 23

* The FDA news about CLDI could be a significant catalyst for the stock, potentially leading to a huge increase tomorrow.
* CLDI's nano float of 600k is currently at $1.52, which is a relatively small number compared to other stocks like MSS, but could still have a significant impact on the stock's price.
* CLDI's recent registered direct offering has raised $1.2 million, with shares being sold at $1.17 per share, which could have implications for the stock's price and the company's financial situation.

Newcomers· Jul 24

Newcomers to CLDI are excited about its potential for a large price increase, with some predicting a spike to $0.17 or higher.
The company has announced a reverse stock split to boost investor appeal, and some users are optimistic about its prospects for a cancer cure.
Users are discussing the company's strong base formation and creeping up in price, with some predicting a "run" or accumulation opportunity.

Generated by AI

Calidi Biotherapeutics

Social

Sep 23

Bullish· May 27

Bearish· May 27

Announcements· Jul 29

Technical Analysis· Jul 29

Regulars· Sep 23

Newcomers· Jul 24

Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering

Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference

Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers

Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026

Also Discussed

Calidi Biotherapeutics, Inc.

Company Information

Location

Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering

Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference

Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers

Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026

Also Discussed

Social

Sep 23

Bullish· May 27

Bearish· May 27

Announcements· Jul 29

Technical Analysis· Jul 29

Regulars· Sep 23

Newcomers· Jul 24